Should I Buy VYGR? VYGR 2026 Analysis

Should You Buy Voyager Therapeutics Inc (VYGR) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

3.970

1 Day change

0.76%

52 Week Range

5.780

Analysis Updated At

2026/01/26

Voyager Therapeutics Inc (VYGR) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has potential catalysts in its pipeline and a strong cash position, the recent financial performance shows a significant revenue drop, and the technical indicators do not suggest a clear upward trend. Additionally, options data and trading sentiment are neutral, and there are no recent positive news or influential trades to support a strong buy decision.

Technical Analysis

The MACD is slightly positive and expanding, indicating mild bullish momentum. RSI is neutral at 54.424, and moving averages are converging, suggesting no strong trend. The stock is trading near its pivot point of 3.906, with resistance at 4.166 and support at 3.647. Overall, the technical indicators do not provide a clear buy signal.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

The company has advanced its NeuroShuttle non-viral delivery technology and has upcoming preclinical and trial data presentations that could act as inflection points. It also has a strong cash position with operational runway into 2028 and potential partner milestones worth up to $2.4B.

Neutral/Negative Catalysts

The stock has an 80% chance of declining in the short term (-2.84% in the next day, -5.97% in the next week). No significant news, hedge fund activity, or insider trading trends have been observed recently.

Financial Performance

In Q3 2025, revenue dropped by 45.73% YoY to $13.37M. However, net income improved significantly, up 208.40% YoY to -$27.89M, and EPS increased by 193.75% YoY to -0.47. Gross margin remained steady at 100%. While there are improvements in profitability metrics, the revenue decline is concerning.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts have mixed views. Morgan Stanley raised the price target to $39, citing potential benefits from the Space Superiority Executive Order, but maintains an Equal Weight rating. H.C. Wainwright lowered the price target to $25 but retains a Buy rating, highlighting strong Q3 results and upcoming milestones. Leerink lowered the price target to $11 but keeps an Outperform rating, citing progress in Alzheimer's programs and the NeuroShuttle platform.

7 Analyst Rating

Wall Street analysts forecast VYGR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VYGR is 13.2 USD with a low forecast of 8 USD and a high forecast of 25 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

0 Hold

0 Sell

Strong Buy

Current: 3.940

Low

Averages

13.2

High

Current: 3.940

Low

Averages

13.2

High

Morgan Stanley

Equal Weight

maintain

$25 -> $39

AI Analysis

2026-01-16

Reason

Morgan Stanley

Price Target

$25 -> $39

AI Analysis

2026-01-16

maintain

Equal Weight

Reason

Morgan Stanley raised the firm's price target on Voyager Technologies to $39 from $25 and keeps an Equal Weight rating on the shares. In the Infrastructure market of Space Technology, the recently-introduced Space Superiority Executive Order should prove supportive overall, but investors are monitoring the extent to which the objectives outlined tangibly impact the opportunity set, the analyst says.

H.C. Wainwright

Buy

downgrade

$30 -> $25

2025-11-12

Reason

H.C. Wainwright

Price Target

$30 -> $25

2025-11-12

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Voyager Therapeutics to $25 from $30 and keeps a Buy rating on the shares. Voyager reported strong Q3 results, ending the quarter with $229M in cash and operational runway into 2028, while remaining eligible for up to $2.4B in partner milestones, the analyst tells investors in a research note. The company also advanced its NeuroShuttle non-viral delivery technology, with upcoming preclinical and trial data presentations expected to drive potential inflection points, the firm says.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for VYGR

Unlock Now

VYGR Should I Buy

VYGR Should I Buy

Should You Buy Voyager Therapeutics Inc (VYGR) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch